Accéder au contenu
Merck
Toutes les photos(1)

Documents

28266

Sigma-Aldrich

Levofloxacin

98.0-102.0% anhydrous basis (HPLC)

Synonyme(s) :

Levofloxacin Anhydrous, (−)-Ofloxacin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C18H20FN3O4
Numéro CAS:
Poids moléculaire :
361.37
Numéro Beilstein :
7327015
Numéro MDL:
Code UNSPSC :
51102829
ID de substance PubChem :
Nomenclature NACRES :
NA.85

Source biologique

synthetic

Niveau de qualité

Pureté

98.0-102.0% anhydrous basis (HPLC)

Forme

powder or crystals

Couleur

light yellow-white to yellow-white

Spectre d'activité de l'antibiotique

Gram-negative bacteria
Gram-positive bacteria

Mode d’action

enzyme | inhibits

Chaîne SMILES 

OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

Clé InChI

GSDSWSVVBLHKDQ-JTQLQIEISA-N

Informations sur le gène

human ... KCNH1(3756)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic , antibiotic resistance , and resistance prevention studies. Antibiotic against bacterial respiratory tract infections.

Actions biochimiques/physiologiques

Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

Conditionnement

10mg, 1g, 10g

Autres remarques

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

Pictogrammes

Health hazardExclamation mark

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 4 Oral - Resp. Sens. 1A - Skin Sens. 1A

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Miriam Hurst et al.
Drugs, 62(14), 2127-2167 (2002-09-25)
Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less
George G Zhanel et al.
Drugs, 62(1), 13-59 (2002-01-16)
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still maintains the best in vitro activity
Takeshi Hirano et al.
International journal of pharmaceutics, 351(1-2), 113-118 (2007-11-06)
L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner membrane followed by fatty acid beta-oxidation. It is known that members of the OCTN family play an important role in
M H Gotfried et al.
Chest, 119(4), 1114-1122 (2001-04-11)
To determine the steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Multiple-dose, open-label, randomized pharmacokinetic study. Thirty-six healthy, nonsmoking adult subjects were randomized either to oral levofloxacin, 500 or 750 mg once daily
Gregory S Basarab et al.
Scientific reports, 5, 11827-11827 (2015-07-15)
With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea

Articles

Quinolones are a key group of antibiotics that interfere with DNA synthesis by inhibiting topoisomerase, most frequently topoisomerase II (DNA gyrase), an enzyme involved in DNA replication.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique